| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3909595 | The Breast | 2009 | 5 Pages |
Abstract
Osteonecrosis of the jaw (ONJ) is a rare but severe disease which has been diagnosed in women with breast cancer on a bisphosphonate (BP) therapy. Thus, the German society of senology appointed a multidisciplinary task force to establish a consensus on the use of bisphosphonates in breast cancer patients with bone metastases, considering in particular the possible risk of ONJ. This report summarizes the results and recommendations for the prevention and treatment of ONJ in breast cancer patients receiving BP.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
T. Fehm, D. Felsenberg, M. Krimmel, E. Solomayer, D. Wallwiener, P. Hadjii,